Stockscreener 앱 받기
7.22
0.41%
-0.03
시간 외 거래:
7.16
-0.06
-0.83%
Biocryst Pharmaceuticals Inc 주식(BCRX)의 최신 뉴스
How high can BioCryst Pharmaceuticals Inc. stock goAnalyst Downgrade & Fast Entry High Yield Stock Tips - newser.com
Multi factor analysis applied to BioCryst Pharmaceuticals Inc.Earnings Performance Report & AI Driven Stock Movement Reports - newser.com
Has BioCryst Pharmaceuticals Inc. formed a bullish divergenceTrade Analysis Report & Risk Managed Investment Signals - newser.com
How BioCryst Pharmaceuticals Inc. stock reacts to oil pricesAnalyst Upgrade & Proven Capital Preservation Tips - newser.com
Weiss Ratings Reiterates "Sell (D-)" Rating for BioCryst Pharmaceuticals (NASDAQ:BCRX) - MarketBeat
RBC Capital Sticks to Their Buy Rating for BioCryst (BCRX) - The Globe and Mail
Is BioCryst Pharmaceuticals Inc. stock poised for growthJuly 2025 Patterns & Stock Portfolio Risk Management - newser.com
BioCryst Pharma Nears Defining FDA Moment For Pediatric HAE Therapy - RTTNews
Quantitative breakdown of BioCryst Pharmaceuticals Inc. recent moveDip Buying & Low Drawdown Trading Techniques - newser.com
RBC Lifts Price Target on BioCryst Pharmaceuticals to $14 From $13, Keeps Outperform Rating - MarketScreener
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Rating Upgraded by Zacks Research - MarketBeat
BioCryst Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Volatility - Markets Mojo
Down 14.3% in 4 Weeks, Here's Why BioCryst (BCRX) Looks Ripe for a Turnaround - Yahoo Finance
Custom strategy builders for tracking BioCryst Pharmaceuticals Inc.Weekly Trade Summary & Technical Pattern Based Signals - newser.com
BioCryst Pharmaceuticals Inc. stock chart pattern explainedJuly 2025 Momentum & AI Powered Buy and Sell Recommendations - newser.com
Applying chart zones and confluence areas to BioCryst Pharmaceuticals Inc.July 2025 Short Interest & Technical Entry and Exit Tips - newser.com
BioCryst Pharmaceuticals (BCRX): Exploring Valuation After Recent Share Price Drift - Sahm
Will earnings trigger a reversal in BioCryst Pharmaceuticals Inc.July 2025 Big Picture & Safe Entry Momentum Stock Tips - newser.com
BioCryst Sells European ORLADEYO Business for $250M Upfront to Focus on US Market - Insider Monkey
JMP Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $18 - 富途牛牛
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
How to monitor BioCryst Pharmaceuticals Inc. with trend dashboardsQuarterly Profit Review & Low Risk Entry Point Guides - newser.com
BioCryst (BCRX) Grants Stock Options and RSUs to New Employees - GuruFocus
Is BioCryst Pharmaceuticals Inc. showing signs of accumulationQuarterly Market Summary & Verified Momentum Watchlists - newser.com
115,000 Options & 91,450 RSUs — BioCryst Grants Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Stock Titan
BioCryst Pharmaceuticals Enters Oversold Territory (BCRX) - Nasdaq
Biocryst sells European rights to HAE therapy Orladeyo for $250M - Angioedema News
BioCryst Sells European ORLADEYO Business for $250M - The Globe and Mail
10 Best Stocks to Buy Under $20 - Insider Monkey
BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Down 4.2%Here's Why - MarketBeat
Neopharmed Gentili completes acquisition of the European ORLADEYO® business from BioCryst Pharmaceuticals - firstonline.info
Top chart patterns to watch in BioCryst Pharmaceuticals Inc.Market Risk Report & Reliable Intraday Trade Alerts - newser.com
BioCryst Pharmaceuticals (NASDAQ:BCRX) Given "In-Line" Rating at Evercore ISI - MarketBeat
BioCryst (BCRX) Finalizes European ORLADEYO Business Sale - GuruFocus
BioCryst Pharmaceuticals Closes $250 Million Sale of Orladeyo Business in Europe - MarketScreener
Evercore ISI Downgrades BioCryst Pharmaceuticals to In Line From Outperform, Lifts Price Target to $8 From $12 - MarketScreener
BioCryst completes $250 million sale of European ORLADEYO business By Investing.com - Investing.com Nigeria
H.C. Wainwright Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $30 - 富途牛牛
BioCryst completes $250 million sale of European ORLADEYO business - Investing.com
Biocryst completes sale of European Orladeyo (berotralstat) business - MarketScreener
BioCryst Pharmaceuticals Completes $250 Million Sale of European ORLADEYO Business to Neopharmed Gentili - Quiver Quantitative
BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business - GlobeNewswire
$250M Deal: BioCryst Divests European ORLADEYO Business at 5.4x Sales Multiple, Retains US Focus - Stock Titan
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
1.54%
1.20%
자본화:
|
볼륨(24시간):